The Laboratory for Tumor Molecular Diagnosis, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, China.
Department of Radiotherapy, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, China.
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):990-998. doi: 10.1158/1055-9965.EPI-19-1148. Epub 2020 Feb 17.
Early diagnosis can significantly reduce colorectal cancer deaths. We sought to identify serum PIWI-interacting RNAs (piRNAs) that could serve as sensitive and specific noninvasive biomarkers for early colorectal cancer detection.
We screened the piRNA expression profile in sera from 7 patients with colorectal cancer and 7 normal controls using small RNA sequencing. Differentially expressed piRNAs were measured in a training cohort of 140 patients with colorectal cancer and 140 normal controls using reverse transcription quantitative PCR. The identified piRNAs were evaluated in two independent validation cohorts of 180 patients with colorectal cancer and 180 normal controls. Finally, the diagnostic value of the identified piRNAs for colorectal adenoma (CRA) was assessed, and their expression was measured in 50 patients with lung cancer, 50 with breast cancer, and 50 with gastric cancer.
The piRNAs piR-020619 and piR-020450 were consistently elevated in sera of patients with colorectal cancer as compared with controls. A predicative panel based on the two piRNAs was established that displayed high diagnostic accuracy for colorectal cancer detection. The two-piRNA panel could detect small-size and early-stage colorectal cancer with an area under the ROC curve of 0.863 and 0.839, respectively. Combined use of the two piRNAs could effectively distinguish CRA from controls. Aberrant elevation of the two piRNAs was not observed in sera of patients with lung, breast, and gastric cancer.
Serum piR-020619 and piR-020450 show a strong potential as colorectal cancer-specific early detection biomarkers.
The field of circulating piRNAs could allow for novel tumor biomarker development.
早期诊断可以显著降低结直肠癌的死亡率。我们试图确定可以作为早期结直肠癌检测敏感和特异性非侵入性生物标志物的血清 PIWI 相互作用 RNA(piRNA)。
我们使用小 RNA 测序筛选了 7 例结直肠癌患者和 7 例正常对照者血清中的 piRNA 表达谱。使用逆转录定量 PCR 在 140 例结直肠癌患者和 140 例正常对照者的训练队列中测量差异表达的 piRNA。在两个独立的验证队列中(180 例结直肠癌患者和 180 例正常对照者)评估了鉴定的 piRNA。最后,评估了鉴定的 piRNA 对结直肠腺瘤(CRA)的诊断价值,并在 50 例肺癌、50 例乳腺癌和 50 例胃癌患者中测量了它们的表达。
与对照组相比,piRNA piR-020619 和 piR-020450 在结直肠癌患者的血清中持续升高。基于这两个 piRNA 的预测性面板建立了一个高准确性的诊断模型,用于检测结直肠癌。该两 piRNA 模型能够检测小尺寸和早期结直肠癌,ROC 曲线下面积分别为 0.863 和 0.839。两个 piRNA 的联合使用可以有效地将 CRA 与对照组区分开来。在肺癌、乳腺癌和胃癌患者的血清中未观察到这两个 piRNA 的异常升高。
血清 piR-020619 和 piR-020450 具有作为结直肠癌特异性早期检测生物标志物的强大潜力。
循环 piRNA 领域可能为新型肿瘤生物标志物的开发提供了可能。